Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aims and background. To compare the outcome of concurrent versus sequential administration of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Methods. From February 1992 to January 2002, 156 patients underwent CMF chemotherapy and radiotherapy, either concurrently (CCRT group, 88 patients) or sequentially (SCRT group, 68 patients). There was a predilection of patients with a larger tumor (P = 0.0035), with more frequent nodal involvement (P = 0.0686), and younger age (P = 0.0776) in the CCRT group. Results. The planned radiotherapy was completed in every patient. No grade 3 or 4 late treatment-related toxicity was observed in the CCRT or SCRT group. Compliance to the treatment as well as cosmetic outcome of the two groups were comparable. Despitemore adverse factors for local-regional recurrence in the CCRT group, the 5-year local-regional control rate of the CCRT group was similar to that of the SCRT group (97.7% vs 93.8%, respectively, P = 0.1688). On multivariate analysis, concomitant administration of chemotherapy and radiotherapy was associated with improved localregional control (P = 0.0463). Conclusions. Concurrent administration of CMF chemotherapy and radiotherapy resulted in improved local-regional control over sequential administration without an increase in significant toxicity. Concurrent CMF chemoradiotherapy may serve as a viable option for patients at high-risk of local-regional relapse not suitable for anthracycline or taxane-based chemotherapy.

Original languageEnglish
Pages (from-to)280-285
Number of pages6
JournalTumori
Volume97
Issue number3
DOIs
StatePublished - 1 May 2011

Fingerprint

Segmental Mastectomy
Methotrexate
Fluorouracil
Cyclophosphamide
Radiotherapy
Breast Neoplasms
Drug Therapy
Recurrence
Anthracyclines
Chemoradiotherapy
Cosmetics
Multivariate Analysis
Therapeutics
Neoplasms

Keywords

  • Breast-conserving surgery
  • Chemotherapy
  • Radiotherapy
  • Sequence

Cite this

@article{a1c01dd07754475593caa4e0e5e9243c,
title = "Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer",
abstract = "Aims and background. To compare the outcome of concurrent versus sequential administration of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Methods. From February 1992 to January 2002, 156 patients underwent CMF chemotherapy and radiotherapy, either concurrently (CCRT group, 88 patients) or sequentially (SCRT group, 68 patients). There was a predilection of patients with a larger tumor (P = 0.0035), with more frequent nodal involvement (P = 0.0686), and younger age (P = 0.0776) in the CCRT group. Results. The planned radiotherapy was completed in every patient. No grade 3 or 4 late treatment-related toxicity was observed in the CCRT or SCRT group. Compliance to the treatment as well as cosmetic outcome of the two groups were comparable. Despitemore adverse factors for local-regional recurrence in the CCRT group, the 5-year local-regional control rate of the CCRT group was similar to that of the SCRT group (97.7{\%} vs 93.8{\%}, respectively, P = 0.1688). On multivariate analysis, concomitant administration of chemotherapy and radiotherapy was associated with improved localregional control (P = 0.0463). Conclusions. Concurrent administration of CMF chemotherapy and radiotherapy resulted in improved local-regional control over sequential administration without an increase in significant toxicity. Concurrent CMF chemoradiotherapy may serve as a viable option for patients at high-risk of local-regional relapse not suitable for anthracycline or taxane-based chemotherapy.",
keywords = "Breast-conserving surgery, Chemotherapy, Radiotherapy, Sequence",
author = "Kyubo Kim and Chie, {Eui Kyu} and Wonshik Han and Dongyoung Noh and Do-Youn Oh and Seock-Ah Im and Taeyou Kim and Bang, {Yung Jue} and Ha, {Sung W.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1700/912.10022",
language = "English",
volume = "97",
pages = "280--285",
journal = "Tumori",
issn = "0300-8916",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer

AU - Kim, Kyubo

AU - Chie, Eui Kyu

AU - Han, Wonshik

AU - Noh, Dongyoung

AU - Oh, Do-Youn

AU - Im, Seock-Ah

AU - Kim, Taeyou

AU - Bang, Yung Jue

AU - Ha, Sung W.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Aims and background. To compare the outcome of concurrent versus sequential administration of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Methods. From February 1992 to January 2002, 156 patients underwent CMF chemotherapy and radiotherapy, either concurrently (CCRT group, 88 patients) or sequentially (SCRT group, 68 patients). There was a predilection of patients with a larger tumor (P = 0.0035), with more frequent nodal involvement (P = 0.0686), and younger age (P = 0.0776) in the CCRT group. Results. The planned radiotherapy was completed in every patient. No grade 3 or 4 late treatment-related toxicity was observed in the CCRT or SCRT group. Compliance to the treatment as well as cosmetic outcome of the two groups were comparable. Despitemore adverse factors for local-regional recurrence in the CCRT group, the 5-year local-regional control rate of the CCRT group was similar to that of the SCRT group (97.7% vs 93.8%, respectively, P = 0.1688). On multivariate analysis, concomitant administration of chemotherapy and radiotherapy was associated with improved localregional control (P = 0.0463). Conclusions. Concurrent administration of CMF chemotherapy and radiotherapy resulted in improved local-regional control over sequential administration without an increase in significant toxicity. Concurrent CMF chemoradiotherapy may serve as a viable option for patients at high-risk of local-regional relapse not suitable for anthracycline or taxane-based chemotherapy.

AB - Aims and background. To compare the outcome of concurrent versus sequential administration of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Methods. From February 1992 to January 2002, 156 patients underwent CMF chemotherapy and radiotherapy, either concurrently (CCRT group, 88 patients) or sequentially (SCRT group, 68 patients). There was a predilection of patients with a larger tumor (P = 0.0035), with more frequent nodal involvement (P = 0.0686), and younger age (P = 0.0776) in the CCRT group. Results. The planned radiotherapy was completed in every patient. No grade 3 or 4 late treatment-related toxicity was observed in the CCRT or SCRT group. Compliance to the treatment as well as cosmetic outcome of the two groups were comparable. Despitemore adverse factors for local-regional recurrence in the CCRT group, the 5-year local-regional control rate of the CCRT group was similar to that of the SCRT group (97.7% vs 93.8%, respectively, P = 0.1688). On multivariate analysis, concomitant administration of chemotherapy and radiotherapy was associated with improved localregional control (P = 0.0463). Conclusions. Concurrent administration of CMF chemotherapy and radiotherapy resulted in improved local-regional control over sequential administration without an increase in significant toxicity. Concurrent CMF chemoradiotherapy may serve as a viable option for patients at high-risk of local-regional relapse not suitable for anthracycline or taxane-based chemotherapy.

KW - Breast-conserving surgery

KW - Chemotherapy

KW - Radiotherapy

KW - Sequence

UR - http://www.scopus.com/inward/record.url?scp=79960870878&partnerID=8YFLogxK

U2 - 10.1700/912.10022

DO - 10.1700/912.10022

M3 - Article

C2 - 21789003

AN - SCOPUS:79960870878

VL - 97

SP - 280

EP - 285

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -